← Back to patent-cliff list
Lumasiran sodium
Tier C — Watch / tradeLumasiran sodium
Alnylam Pharmaceuticals Inc
Originator
2020
First approval
-
Expiry (public)
No sales data
Peak sales
Nucleic acid drug
Type
Targets：HAO1
Brand：OXLUMO
Indications (approved)：原发性高草酸尿症
Regional status
US
Approved
2020-11-23
EU
Approved
2020-11-19
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Lumasiran sodium?
Approved indications include: 原发性高草酸尿症.
When does the Lumasiran sodium patent expire?
No public expiry year is available for Lumasiran sodium yet; this page updates once verified.
How do I get a quote for Lumasiran sodium intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27